^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Rectal Cancer
    Drug:Tyvyt (sintilimab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

    Excerpt:
    ...Cohort 1: Biopsy tissues with IHC indicates deficient mismatch repair(dMMR),that is,the loss of at least one of the four proteins ,MSH1,MSH2,MSH6,PMS2;or gene detection implies MSI-H; Cohort 2: Biopsy tissues with IHC indicates proficient mismatch repair(pMMR),that is positivity of all four proteins ,MSH1,MSH2,MSH6,PMS2;or gene detection implies MSS/MSI-L 3....
    Trial ID:
    B2019-149
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

    Excerpt:
    ...With DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) status, whether or...
    Trial ID:
    NCT04636008
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    The safety and efficacy of Sintilimab combined with hypofractionated radiotherapy in MSI-H/dMMR rectal cancer: a prospective, single-arm, multicenter, phase Ib study

    Excerpt:
    ...The patients diagnosed as dMMR by immunohistochemistry or MSI-H (PCR or NGS) by gene detection whatever it's Lynch syndrome or not; 3. ...
    Trial ID:
    ChiCTR2000037604
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lancet Gastroenterol Hepatol
    Title:

    Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study

    Published date:
    03/01/2023
    Excerpt:
    Patients aged 18-75 years with mismatch-repair deficient or microsatellite instability-high locally advanced rectal cancer were enrolled and received neoadjuvant sintilimab monotherapy...A complete response was thus noted for 12 (75%; 95% CI 47-92) of 16 patients....The preliminary results of this study suggest that anti-PD-1 monotherapy is effective and tolerable for patients with mismatch-repair deficient locally advanced rectal cancer...
    DOI:
    10.1016/S2468-1253(22)00439-3
    Trial ID:
    B2019-149
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Pd1 antibody sintilimab for dMMR/MSI-H locally advanced rectal cancer: An open-label, phase 2, single-arm study (cohort A)

    Published date:
    05/19/2021
    Excerpt:
    Pd1 antibody sintilimab achieved 4CR (pCR+cCR) in 6 dMMR/MSI-H LARC patients.
    DOI:
    10.1200/JCO.2021.39.15_suppl.e15602
    Trial ID:
    B2019-149